The blood–brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal
brain. However, the importance of the BBB in limiting drug delivery and efficacy is …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Background Standard therapy for newly diagnosed glioblastoma is radiotherapy plus
temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab …

Glioblastoma multiforme (GBM) is the most aggressive type of primary brain tumor and is
associated with a poor clinical prognosis. Despite the progress in the understanding of the …

Tumors are being increasingly perceived as abnormal organs that, in many respects,
recapitulate the outgrowth and differentiation patterns of normal tissues. In line with this idea …

Background: Glioblastoma multiforme (GBM) is the most common and lethal primary
malignancy of the central nervous system (CNS). Despite the proven benefit of surgical …

Metabolic reprogramming is a hallmark of cancer. Oncogenic growth signaling regulates
glucose, glutamine and lipid metabolism to meet the bioenergetics and biosynthetic …

Glioblastoma (GBM) is the most common and highly lethal primary malignant brain tumor in
adults. There is a dire need for easily accessible, noninvasive biomarkers that can delineate …

Purpose To demonstrate that magnetic resonance (MR) imaging–monitored transcranial
focused ultrasound can enhance the delivery of the antiangiogenic monoclonal antibody …

Purpose: Glioblastoma (GBM) is a heterogeneous malignancy with multiple subpopulations
of cancer cells present within any tumor. We present the results of a phase I clinical trial …